SUTRO BIOPHARMA, INC. Basic Shares Outstanding (Weighted Average)
SUTRO BIOPHARMA, INC. (STRO) reported Basic Shares Outstanding (Weighted Average) of 16.57 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 16.57M shares, a 94.69% increase year-over-year.
- SUTRO BIOPHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 13.08M shares, a 56.41% increase year-over-year.
- SUTRO BIOPHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was -218.58M shares.
- SUTRO BIOPHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 84.87M shares, a 3.44% increase year-over-year.
- SUTRO BIOPHARMA, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 8.50M shares, a 9.84% increase from fiscal 2024.
- SUTRO BIOPHARMA, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 7.74M shares, a 87.14% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 60.16M shares, a 18.57% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 50.74M shares, a 10.02% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 16.57M shares 10-Q · filed 2026-08-12 | 14.84M shares 10-Q · filed 2026-08-12 | -62.98M shares derived: average of 3 quarters · filed 2026-08-12 | -26.01M shares derived: average of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | 13.08M shares 10-Q · filed 2026-05-14 | -102.75M shares derived: average of 2 quarters · filed 2026-05-14 | -40.21M shares derived: average of 3 quarters · filed 2026-05-14 | -28.03M shares derived: average of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | -218.58M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -66.86M shares derived: average of 2 quarters · filed 2026-03-23 | -41.73M shares derived: average of 3 quarters · filed 2026-08-12 | 8.50M shares 10-K · filed 2026-03-23 | |||
| 2025-09-30 | 84.87M shares 10-Q · filed 2025-11-06 | 46.69M shares derived: average of 2 quarters · filed 2026-08-12 | 84.19M shares 10-Q · filed 2025-11-06 | -23.03M shares derived: average of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | 8.51M shares 10-Q · filed 2026-08-12 | 84.58M shares 10-Q · filed 2025-08-07 | 8.48M shares 10-Q · filed 2026-08-12 | 83.85M shares 10-Q · filed 2025-08-07 | -58.99M shares derived: average of 3 quarters · filed 2026-08-12 | -23.73M shares derived: average of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | 8.36M shares 10-Q · filed 2026-05-14 | 83.11M shares 10-Q · filed 2025-05-08 | -92.75M shares derived: average of 2 quarters · filed 2026-05-14 | -34.48M shares derived: average of 3 quarters · filed 2026-05-14 | -5.56M shares derived: average of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -193.86M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -55.91M shares derived: average of 2 quarters · filed 2026-03-23 | -10.20M shares derived: average of 3 quarters · filed 2026-03-23 | 7.74M shares 10-K · filed 2026-03-23 | 76.83M shares 10-K · filed 2025-03-13 | ||
| 2024-09-30 | 82.04M shares 10-Q · filed 2025-11-06 | 81.63M shares derived: average of 2 quarters · filed 2025-11-06 | 74.93M shares 10-Q · filed 2025-11-06 | 71.42M shares derived: average of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | 81.22M shares 10-Q · filed 2025-08-07 | 71.34M shares 10-Q · filed 2025-08-07 | 67.88M shares derived: average of 3 quarters · filed 2025-08-07 | 66.06M shares derived: average of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | 61.46M shares 10-Q · filed 2025-05-08 | 61.21M shares derived: average of 2 quarters · filed 2025-05-08 | 61.01M shares derived: average of 3 quarters · filed 2025-05-08 | 60.84M shares derived: average of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | 60.97M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 60.79M shares derived: average of 2 quarters · filed 2025-03-13 | 60.64M shares derived: average of 3 quarters · filed 2025-03-13 | 60.16M shares 10-K · filed 2025-03-13 | |||
| 2023-09-30 | 60.60M shares 10-Q · filed 2024-11-13 | 60.47M shares derived: average of 2 quarters · filed 2024-11-13 | 59.89M shares 10-Q · filed 2024-11-13 | 59.19M shares derived: average of 4 quarters · filed 2025-03-13 | |||
| 2023-06-30 | 60.34M shares 10-Q · filed 2024-08-13 | 59.54M shares 10-Q · filed 2024-08-13 | 58.72M shares derived: average of 3 quarters · filed 2025-03-13 | 57.12M shares derived: average of 4 quarters · filed 2025-03-13 | |||
| 2023-03-31 | 58.72M shares 10-Q · filed 2024-05-13 | 57.91M shares derived: average of 2 quarters · filed 2025-03-13 | 56.05M shares derived: average of 3 quarters · filed 2025-03-13 | 53.78M shares derived: average of 4 quarters · filed 2025-03-13 | |||
| 2022-12-31 | 57.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 54.72M shares derived: average of 2 quarters · filed 2025-03-13 | 52.13M shares derived: average of 3 quarters · filed 2025-03-13 | 50.74M shares 10-K · filed 2025-03-13 | |||
| 2022-09-30 | 52.35M shares 10-Q · filed 2023-11-13 | 49.65M shares derived: average of 2 quarters · filed 2023-11-13 | 48.62M shares 10-Q · filed 2023-11-13 | 48.02M shares derived: average of 4 quarters · filed 2024-03-25 | |||
| 2022-06-30 | 46.96M shares 10-Q · filed 2023-08-10 | 46.73M shares 10-Q · filed 2023-08-10 | 46.58M shares derived: average of 3 quarters · filed 2024-03-25 | 46.48M shares derived: average of 4 quarters · filed 2024-03-25 | |||
| 2022-03-31 | 46.50M shares 10-Q · filed 2023-05-15 | 46.40M shares derived: average of 2 quarters · filed 2024-03-25 | 46.32M shares derived: average of 3 quarters · filed 2024-03-25 | 46.27M shares derived: average of 4 quarters · filed 2024-03-25 | |||
| 2021-12-31 | 46.30M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 46.23M shares derived: average of 2 quarters · filed 2024-03-25 | 46.19M shares derived: average of 3 quarters · filed 2024-03-25 | 46.12M shares 10-K · filed 2024-03-25 | |||
| 2021-09-30 | 46.16M shares 10-Q · filed 2022-11-08 | 46.14M shares derived: average of 2 quarters · filed 2022-11-08 | 46.06M shares 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | 46.12M shares 10-Q · filed 2022-08-08 | 46.01M shares 10-Q · filed 2022-08-08 | |||||
| 2020-12-31 | 40.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 38.60M shares derived: average of 2 quarters · filed 2023-03-30 | 35.70M shares derived: average of 3 quarters · filed 2023-03-30 | 32.57M shares 10-K · filed 2023-03-30 | |||
| 2020-09-30 | 36.89M shares 10-Q · filed 2021-11-10 | 33.39M shares derived: average of 2 quarters · filed 2021-11-10 | 29.99M shares 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | 29.90M shares 10-Q · filed 2021-08-09 | 26.51M shares 10-Q · filed 2021-08-09 | |||||
| 2019-09-30 | 22.95M shares 10-Q · filed 2020-11-05 | 22.94M shares derived: average of 2 quarters · filed 2020-11-05 | 22.91M shares 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | 22.93M shares 10-Q · filed 2020-08-06 | 22.90M shares 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |